{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T22:29:12Z","timestamp":1758925752816},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1001\/jamaophthalmol.2018.6915","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T21:26:28Z","timestamp":1549574788000},"page":"407","source":"Crossref","is-referenced-by-count":2,"title":["Understanding Ocular Inflammation in Eyes Treated With Intravitreal Gene Therapy"],"prefix":"10.1001","volume":"137","author":[{"given":"Jacque L.","family":"Duncan","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"10097","key":"eic180076r1","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"eic180076r2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamaophthalmol.2016.5659","article-title":"Visual consequences of delivering therapies to the subretinal space.","volume":"135","author":"Duncan","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"189","key":"eic180076r3","doi-asserted-by":"publisher","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous.","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci Transl Med"},{"key":"eic180076r4","article-title":"Immune response and intraocular inflammation in patients with Leber hereditary optic neuropathy treated with intravitreal injection of recombinant adeno-associated virus 2 carrying the ND4 gene: a secondary analysis of a phase 1\/2 clinical trial","author":"Bouquet","journal-title":"JAMA Ophthalmol"},{"key":"eic180076r5","first-page":"1165","article-title":"Leber hereditary optic neuropathy: current perspectives.","volume":"9","author":"Meyerson","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"eic180076r6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ophtha.2017.12.036","article-title":"Safety of rAAV2\/2-ND4 gene therapy for Leber hereditary optic neuropathy.","volume":"125","author":"Vignal","year":"2018","journal-title":"Ophthalmology"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaophthalmology\/article-pdf\/137\/4\/407\/17459325\/jamaophthalmology_duncan_2019_ic_180076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T02:29:16Z","timestamp":1555036156000},"score":1,"resource":{"primary":{"URL":"http:\/\/archopht.jamanetwork.com\/article.aspx?doi=10.1001\/jamaophthalmol.2018.6915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.6915","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}